Catalyst overview
Research summary
This catalyst tracks a Phase 1 update for SION-451 in Cystic fibrosis . The expected timing is based on the latest available company guidance and may change.
6/4/25- Initiate Ph1 in healthy volunteers in H2 2025. 8/25/25- First patient dosed. 10/24/25- PK data reported. Topline data in mid-2026. 03/02/26:- Ph1 dual-combination trial with SION-2222 and SION-109 ongoing; topline data still expected Mid-2026. 05/12/26:- NCT07035990 Ph1 dual-combination trial ongoing; topline data still expected summer 2026. Encore Ph1 data at ECFS. 08/06/26:- NCT07035990 Ph1 dual-combination topline data remain on track for Summer 2026. 08/10/26:- Ph1 dual-combo data met safety/PK goals; SION-451+SION-2222 preferred. Next steps under evaluation.
Verification
Confirm timing and program details against the company announcement or filing.